Technology | January 16, 2013

Lantheus Introduces Low-Enriched Uranium (LEU) Tc-99m Generator

Supports long-term strategy to eliminate use of highly enriched uranium (HEU)-produced molybdenum and technetium

Lantheus LEU TechneLite generator Mo-99 Nuclear Imaging Radiopharmeceuticals

January 16, 2013 — Lantheus Medical Imaging Inc. has added a low-enriched uranium (LEU) TechneLite (technetium Tc 99m Generator) generator to the its nuclear imaging product portfolio. Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.

With the introduction of the LEU TechneLite generator, Lantheus fully supports the U.S. government’s global nuclear security strategy to encourage reliable supplies of medical radioisotopes produced from non-HEU sources. On Jan. 2, 2013, President Obama signed into law the American Medical Isotopes Production Act of 2011 (AMIPA) as part of the 2013 National Defense Authorization Act. The AMIPA encourages the domestic production of LEU Mo-99 and provides for the eventual prohibition of the export of HEU from the United States. In addition, the Centers for Medicare and Medicaid Services (CMS) recently stipulated in the 2013 final Medicare payment rules, for Medicare Hospital Outpatients, that CMS will provide incremental reimbursement for every Tc-99m diagnostic dose produced from non-HEU sourced Mo-99. Lantheus’ LEU TechneLite generator satisfies the new reimbursement requirements under the CMS 2013 rules.

“We are pleased to be the first company to offer a Tc-99m generator produced using at least 95 percent LEU,” said Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “As leaders in nuclear medicine, an important component of our global sourcing strategy is to increase our use of LEU-sourced Mo-99 with a goal of 100 percent by 2016. Our TechneLite generator is used in many critical diagnostic imaging procedures, including scans of the heart, brain, bone, kidneys and some types of tumors. The introduction of our LEU TechneLite generator expands our nuclear medicine product portfolio and meets CMS’ new reimbursement requirements for Medicare Hospital Outpatients in 2013, while supporting the government’s non-proliferation goal of moving away from the use of HEU in the production of medical isotopes.”

Mo-99 is the parent isotope of Tc-99m, which is the radioisotope most widely used for nuclear imaging tests. Tc-99m is used in approximately 15 million doses in the United States annually. As a leader in the radiopharmaceutical business, Lantheus has secured the most globally diversified and balanced Mo-99 supply chain in the industry, and receives the medical isotope from four of the five major processors and seven of the eight associated reactors.

In 2012, Lantheus announced expanded access to LEU-sourced Mo-99 with an extended agreement with NTP Radioisotopes in South Africa. Under the five-year agreement, Lantheus will receive an increasing supply of Mo-99 produced from LEU targets from NTP Radioisotopes (NTP) and Australian Nuclear Science and Technology Organisation (ANSTO). Additionally, Lantheus announced continued supply of Mo-99 from Nordion, which will be used in the production of the company’s non-LEU TechneLite generators.

“We continue to be committed to providing a stable, balanced and reliable supply of Mo-99 to our customers,” said Cyrille Villeneuve, chief commercial officer of Lantheus Medical Imaging. “Our gradual transition to LEU-sourced Mo-99 and the addition of the LEU TechneLite generator ensures that our customers will have continued access to Tc-99m, now and in the future. We believe our LEU strategy gives us a strong position in the generator market and provides a differentiated offering for our customers.”

For more information: www.technelite.com

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...